Table 3.
Unit | ALS cohort n = 35 | Control cohort n = 34 | Unpaired t-test p-value | |
---|---|---|---|---|
Age (years) | Mean ± SD | 69.54 ± 10.64 | 68.06 ± 9.59 | 0.55 |
Females, n (%) | Frequency | 18 (51.4) | 18 (52.9) | 0.90 |
AHT, n (%) | Frequency | 16 (45.7) | 11 (32.4) | 0.26 |
Diabetes, n (%) | Frequency | 7 (20) | 1 (3) | 0.03 |
LVEDV (ml) | Median (5; 95) | 99 (68; 158.2) | 136 (82.4; 213.6) | 0.0001 |
LVEDV index (ml/m2) | Median (5; 95) | 57.74 (29.09; 88.14) | 73.18 (42.78; 110.6) | <0.0001 |
LVSV (ml) | Mean ± SD | 68.30 ± 17.62 | 82.09 ± 20.66 | 0.0046 |
LVSV index (ml/m2) | Mean ± SD | 37.05 ± 9.737 | 44.75 ± 10.34 | 0.0024 |
Ventricular mass (g) | Mean ± SD | 79.38 ± 26.16 | 99.0 ± 27.30 | 0.0047 |
Ventricular mass index (g/m2) | Mean ± SD | 41.98 ± 16.04 | 50.3 ± 17.36 | 0.0435 |
LVEF (%) | Median (5; 95) | 64 (55.2; 74.7) | 62 (44.4; 75.6) | 0.034 |
RVEDV (ml) | Median (5; 95) | 96 (67; 163.65) | 134 (68.6; 219.2) | 0.0005 |
RVEDV index (ml/m2) | Median (5; 95) | 55.63 (27.35; 88.23) | 77.63 (35.82; 115.7) | <0.0001 |
RVSV (ml) | Mean ± SD | 65.16 ± 18.59 | 82.59 ± 21.87 | 0.001 |
RVSV index (ml/m2) | Mean ± SD | 35.53 ± 10.24 | 45.00 ± 11.06 | 0.0006 |
RVEF (%) | Median (5; 95) | 64 (55.15; 78.4) | 60 (45.4; 80.8) | 0.081 |
T1-ratio | Median (5; 95) | 4.8 (2.0; 14.13) | 3.6 (1.8; 10.6) | 0.076 |
T1 path., n (%) | Frequency | 24/31 (77.4) | 8/30 (26.7) | 0.0001 |
PE, n (%) | Frequency | 7 (21.9) | 6 (17.6) | 0.67 |
LGE, n (%) | Frequency | 8 (23.5) | 3 (9.1) | 0.11 |
AHT, arterial hypertension; LVEDV, left ventricular end-diastolic volume; LVSV, left ventricular stroke volume; LVEF, left ventricular ejection fraction; RVEDV, right-ventricular end-diastolic volume; RVSV, right-ventricular stroke volume; PE, pericardial effusion; LGE, late gadolinium enhancement.
Significant p values < 0.05 are marked in bold. CMR indexes related to body surface areas (BSA), which was calculated by the Dubois and Dubois regression formula:
BSA = 0.007184 × weight (kg)0.425 × height (cm)0.725.